Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Live Attenuated Vaccines Market Heading Into 2029?
Over the past few years, the live attenuated vaccines market has experienced significant growth. The market is predicted to expand from $23.58 billion in 2024 to $25.95 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The surge witnessed in the historical phase can be traced back to heightened global immunization coverage, amplified public health expenditure, raising consciousness towards disease prevention, increased pediatric vaccine demand, and broadening of vaccine programs.
Expectations are high for substantial expansion of the live attenuated vaccines market in the forthcoming years, with projection figures reaching up to $37.56 billion by 2029, following a compound annual growth rate (CAGR) of 9.7%. The growth expected within this forecast period can be associated with several factors including an increased emphasis on preventive healthcare, broader acceptance in low- and middle-income nations, enhanced efforts towards outbreak readiness, a rise in the demand for travel-related vaccinations, and the widespread initiatives by governments for funded immunizations. The forecast period will also witness several significant trends like the progress in vaccine delivery systems, novel developments in genetic attenuation techniques, amplified investment in research and development, emergence of thermostable formulations, and the introduction of digital strategies into immunization programs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp
Which Factors Are Pushing The Live Attenuated Vaccines Market Forward?
The surge in infectious diseases is anticipated to boost the expansion of the live attenuated vaccines market. These diseases, which can be caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can be transferred directly or indirectly from an individual, animal, or environment to another. The quick spread of infectious diseases, primarily due to increasing global travel, is outpacing the efforts to contain their spread. Live attenuated vaccines play a crucial role in the prevention of these diseases by inducing a strong immune response using weakened pathogens, thus ensuring long-lasting immunity and hindering disease transmission. For example, in March 2025, the World Health Organization, an intergovernmental organization based in Switzerland, reported that approximately 10.8 million individuals worldwide suffered from TB in 2023, which included 6.0 million men, 3.6 million women, and 1.3 million children. Thus, the escalating prevalence of infectious diseases is fueling the growth of the live attenuated vaccines market.
Which Segment Held The Largest Share In The Live Attenuated Vaccines Market In 2025?
The live attenuated vaccines market covered in this report is segmented –
1) By Vaccine Type: Monovalent, Multivalent
2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated
3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users
Subsegments:
1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines
2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines
How Are Key Trends Driving Expansion In The Live Attenuated Vaccines Industry?
Leading businesses in the live attenuated vaccines market are concentrating their efforts on creating innovative items such as single-dose vaccines. These were designed to increase the efficiency of immunization and make it easier for patients to comply. Single-dose vaccines offer prolonged immunity with just one shot, effectively eliminating the need for several doses. This makes vaccinations much simpler for patients and healthcare professionals, improving comfort and accessibility. In November 2023, Valneva SE, a French biotech firm that produces vaccines for infectious illnesses, unveiled IXCHIQ, which obtained approval from the US Food and Drug Administration (FDA), an American health organization. This is the first live-attenuated chikungunya vaccine ever produced, created for adults who are 18 years old and above. This approval holds great importance since IXCHIQ is the first authorized vaccine for chikungunya worldwide. It addresses a medical necessity for a preventive measure against this viral disease transmitted by mosquitos, known to induce severe fever, joint and muscle discomfort, and additional symptoms.
Which Organizations Are Driving Progress In The Live Attenuated Vaccines Industry?
Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report
Which Region Is Expected To Experience The Highest Growth In The Live Attenuated Vaccines Industry?
North America was the largest region in the live attenuated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model